drugset / Trial / NCT01842035

Heart Rate Response to Regadenoson and Sudden Cardiac Death

NCT01842035

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to determine whether a blunted heart rate response to regadenoson is an independent predictor of sudden cardiac death.

Timeline

Start
2013-02
Primary completion
2020-04
Completion
2022-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Regadenoson Diagnostic / imaging agent 400 ug Intravenous